Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Parallel, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Moderate to Severe Atopic Dermatitis.

NCT07180511 is registered in ClinicalTrials.gov with E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT07180511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07180511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Parallel, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Moderate to Severe Atopic Dermatitis.
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
March 12, 2025
Completion date
July 19, 2027
Enrollment
460 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad)